HEXABRIX 320 393 MG — DIN 00603740
IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG · GUERBET · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is HEXABRIX 320?
HEXABRIX 320 393 MG contains IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG. It is listed in the Health Canada Drug Product Database under DIN 00603740, held by GUERBET, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as cancelled post market, status dated 08-Jul-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is HEXABRIX 320 used for?
Hexabrix 320: Angiography (cerebral, coronary, peripheral), CT enhancement, urography, arthrography. Hexabrix 200: Phlebography, intra-arterial DSA, and CT enhancement of the body.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Ioxaglic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Ioxaglic Acid — 2 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GUERBET | 2 | 0 | HEXABRIX 200, HEXABRIX 320 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 393 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVASCULAR |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions use of glass or plastic syringes). |
| Storage | Not specified in the provided text. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Ioxaglic Acid |
|---|---|
| ATC code | V08AB03 |
| AHFS class | 36:68.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00603740 |
|---|---|
| DIN (unpadded, as printed on some documents) | 603740 |
| Brand name | HEXABRIX 320 |
| Generic / active ingredient | IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG |
| Market authorization holder | GUERBET |
| Health Canada schedule | Ethical |
| ATC code | V08AB03 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AB |
| Current status | CANCELLED POST MARKET |
| Status date | 08-Jul-2015 |
| Original market date | 1983-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Varies by procedure. Administered intravascularly, intra-arterially, or by direct injection into structures (e.g., joint spaces, uterus). See specific procedure sections for detailed dosing.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Contraindicated for myelography or any intrathecal procedure. Not for use in patients with severe hepatic and renal disease or hypersensitivity to salts of ioxaglic acid.
Warnings and precautions
Serious thromboembolic events (MI, stroke) reported. Risk of severe neurologic sequelae/paralysis. Risk of anuria in multiple myeloma. Caution in pheochromocytoma and sickle cell disease.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEXABRIX 200 | 123 MG | SOLUTION | GUERBET | CANCELLED POST MARKET | 00788805 |
2 · Same class — other molecules in ATC V08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iopamidol | IOPAMIDOL INJECTION USP · ISOVUE 128 INJ 26% · ISOVUE 128 INJECTION · ISOVUE 200 INJ 41% · +8 more | 15 | 5 | Yes |
| Iodixanol | IODIXANOL INJECTION 270 · IODIXANOL INJECTION 320 · VISIPAQUE 270 · VISIPAQUE 320 | 4 | 4 | Yes |
| Iohexol | OMNIPAQUE 180 · OMNIPAQUE 180 LIQ SAR 388MG/ML · OMNIPAQUE 240 · OMNIPAQUE 240 LIQ IV SAR 518MG/ML · +4 more | 8 | 3 | Yes |
| Iopromide | ULTRAVIST 240 · ULTRAVIST 300 · ULTRAVIST 370 | 3 | 2 | Yes |
| Ioversol | OPTIRAY 160 · OPTIRAY 160 (ULTRAJECT) · OPTIRAY 240 · OPTIRAY 240 (ULTRAJECT) · +7 more | 11 | 0 | Not in Canada |
| Iotrolan | OSMOVIST 240 - LIQ INT 513MG/ML · OSMOVIST 300 - LIQ INT 641MG/ML | 2 | 0 | Not in Canada |
| Ioxaglic Acid | HEXABRIX 200 · HEXABRIX 320 | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AA | Diatrizoic Acid · Iotalamic Acid · Ioxitalamic Acid · Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | 41 | 1 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.